Association Limousine pour l'Utilisation du Rein Artificiel à Domicile (ALURAD), Limoges, France.
Centre Hospitalier de la Côte Basque, Bayonne, France.
PLoS One. 2023 Jul 5;18(7):e0287859. doi: 10.1371/journal.pone.0287859. eCollection 2023.
Minimal data are available regarding the prevalence and incidence of anemia among patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) in France.
This was a retrospective non-interventional study of patients with a record of NDD-CKD in the Echantillon Généraliste des Bénéficiaires (EGB) database between January 01, 2012, and December 31, 2017. The primary objective was to estimate the annual incidence and prevalence of anemia of NDD-CKD. Secondary objectives included description of the demographics and clinical characteristics of patients with NDD-CKD-related anemia. An exploratory objective was to use machine learning to identify patients from the general population that might have NDD-CKD but without a recorded ICD-10 diagnosis of CKD.
During 2012-2017, 9865 adult patients in the EGB database had confirmed NDD-CKD; of these, 49.1% (4848/9865) had anemia. From 2015 to 2017, estimates of incidence (108.7-114.7 per 1000 population) and prevalence (435.7-449.5 per 1000 population) of NDD-CKD-related anemia were stable. Less than half of patients with anemia of NDD-CKD were treated with oral iron, and approximately 15% were treated with erythropoiesis-stimulating agents. Based on adult French population projections in 2020 and an estimated prevalence rate in 2017 of 42.2 per 1000 population for confirmed plus possible NDD-CKD (as a proportion of the general French population), the estimated number of patients with possible NDD-CKD in France was 2,256,274, approximately five-fold greater than the number identified by diagnostic codes and hospitalizations.
Anemia of NDD-CKD was shown to be a constant long-term burden in France, and its apparent prevalence may still be significantly underestimated. Given the potential treatment gap, additional initiatives to better identify and treat NDD-CKD anemia may improve patient management and treatment outcomes.
法国非透析依赖性慢性肾脏病（NDD-CKD）患者的贫血患病率和发病率数据很少。
这是一项回顾性非干预性研究，纳入了 2012 年 1 月 1 日至 2017 年 12 月 31 日期间 Echantillon Généraliste des Bénéficiaires（EGB）数据库中记录的 NDD-CKD 患者。主要目的是评估 NDD-CKD 相关贫血的年发病率和患病率。次要目的包括描述 NDD-CKD 相关贫血患者的人口统计学和临床特征。探索性目的是使用机器学习从一般人群中识别可能患有 NDD-CKD 但没有记录 ICD-10 慢性肾脏病诊断的患者。
2012-2017 年，EGB 数据库中有 9865 名成年患者确诊为 NDD-CKD；其中，49.1%（4848/9865）患有贫血。2015 年至 2017 年，NDD-CKD 相关贫血的发病率（每 1000 人 108.7-114.7 人）和患病率（每 1000 人 435.7-449.5 人）估计值稳定。不到一半的 NDD-CKD 贫血患者接受口服铁治疗，约 15%的患者接受促红细胞生成素刺激剂治疗。根据 2020 年法国成年人口预测和 2017 年确诊加可能 NDD-CKD 的估计患病率（占法国总人口的比例）为每 1000 人 42.2 人，法国可能患有 NDD-CKD 的患者人数为 2256274 人，大约是诊断代码和住院患者识别人数的五倍。
NDD-CKD 贫血在法国是一个长期存在的负担，其明显的患病率可能仍然被严重低估。鉴于潜在的治疗差距，采取更多措施更好地识别和治疗 NDD-CKD 贫血可能会改善患者的管理和治疗效果。
